Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2016

View Archived Issues

Asceneuron discloses glycosidase inhibitors

PharmaResearch Products and Lipopeptide establish strategic collaboration in wound care

Scientists report miRNAs that may be associated with mBCC

PsiOxus Therapeutics begins combination treatment in OCTAVE study

Gilead Sciences patents compounds to treat HIV

Han Wha Pharma and Yang Ji Chemical disclose JAK inhibitors

Prexton Therapeutics introduces mGlu4 receptor PAMs

Bristol-Myers Squibb describes HIV integrase inhibitors

University of Dayton reports antineoplastic and antibacterial compounds

AnaptysBio starts dosing in first-in-human phase I trial of ANB-020

Senhwa Biosciences enters agreement with CCTG for phase I/II study of CX-5461

Vericel releases topline results from phase IIb study of ixmyelocel-T

Phase III data show sarilumab superior to adalimumab in patients with active rheumatoid arthritis

FDA accepts for review Enbrel sBLA for pediatric chronic severe plaque psoriasis

Scancell and Karolinska Institutet collaborate to explore role of citrullination in cancer

Double-blind trial evaluates mexiletine in sporadic amyotrophic lateral sclerosis

SRI International awarded National Cancer Institute contract to develop cancer treatments

Bioresorbable sensors may enable wireless data collection in deep tissue and body cavities

Lundbeck initiates phase III program of Lu-AF-35700 for treatment-resistant schizophrenia

Enrollment under way in phase III trial of elafibranor for NASH

Novartis submits sBLA for ofatumumab with fludarabine and cyclophosphamide for relapsed CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...